Use of EBV-infected B lymphocytes and chimeric TCRs to target cancer cells.

In this model, CD8 T cells bearing a G_D2-specific chimeric TCR are activated by EBV antigen binding to a native TCR and are costimulated through the interaction of B7/CD28. They may receive additional cognate help from EBV-specific CD4⁺ T cells. The stimulated chimeric receptor-positive cells are able to recognize and lyse G_D2⁺ tumor cells (such as neuroblastoma) via the corresponding epitope of the chimeric TCR.